UK Markets close in 8 hrs 25 mins

Biodesix, Inc. (BDSX)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
5.67-0.27 (-4.55%)
At close: 04:00PM EST
5.67 0.00 (0.00%)
After hours: 04:00PM EST

Biodesix, Inc.

2970 Wilderness Place
Suite 100
Boulder, CO 80301
United States
303 417 0500

IndustryDiagnostics & Research
Full-time employees200

Key executives

NameTitlePayExercisedYear born
Mr. Scott HuttonPres, CEO & Director531.88kN/A1972
Ms. Robin Harper CowieCFO, Sec. & Treasurer375.24kN/A1980
Mr. Kieran O'KaneChief Commercial Officer310.06kN/A1977
Dr. Heinrich RöderFounder & CTON/AN/AN/A
Mr. Robert E. CawthornFounder & Director EmeritusN/AN/A1935
Mr. Ryan H. SiurekChief Accounting OfficerN/AN/A1972
Mr. Jeffrey A. BojarVP of Legal and Regulatory AffairsN/AN/AN/A
Mr. Matt StaufferVP of SalesN/AN/AN/A
Dr. Paul J. BeresfordChief Bus. OfficerN/AN/AN/A
Dr. Gary Anthony PestanoChief Devel. OfficerN/AN/A1967
Amounts are as of 31 December 2020, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Biodesix, Inc. operates a data-driven diagnostic solutions company in the United States. The company offers blood-based tests across the lung cancer continuum of care, such as Nodify XL2 and Nodify CDT tests to help physicians reclassify risk of malignancy in patients with suspicious lung nodules; and GeneStrat tumor profiling and VeriStrat immune profiling tests that provide physicians with timely results to facilitate treatment decisions. It also provides Bio-Rad SARS-CoV-2 ddPCR test, which is designed to detect the presence of infection by the SARS-CoV-2 virus; and Platelia SARS-CoV-2 Total Ab test, an antibody test for detecting a B-cell immune response to SARS-CoV-2 that indicate recent or prior infection. In addition, the company offers include diagnostic research, clinical research, development, and testing services to biopharmaceutical companies, as well as discovers, develops, and commercializes companion diagnostics. The company was formerly known as Elston Technologies, Inc. Biodesix, Inc. was incorporated in 2005 and is headquartered in Boulder, Colorado.

Corporate governance

Biodesix, Inc.’s ISS governance QualityScore as of 26 September 2021 is 8. The pillar scores are Audit: 4; Board: 6; Shareholder rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.